Although approved biologic agents differ by countries, biologic agents commonly used for the treatment of psoriasis are categorized into three groups, tumor necrosis factor (TNF)-α inhibitors, interleukin (IL)-23 inhibitors, and IL-17 inhibitors, as shown in Table 1. The gene discussed is IL17A; the disease is psoriasis.